糖皮质激素对社区获得性肺炎死亡率和临床治愈的影响:随机对照试验的系统评价、荟萃分析与荟萃回归
该系统评价与荟萃分析检索了PubMed、Cochrane Library和Embase,纳入16项随机对照试验,比较全身性糖皮质激素与标准治疗在社区获得性肺炎(CAP)住院患者中的效果。主要终点全因死亡率无显著差异(16项研究[3842例];RR 0.85;95%CI 0.67-1.07;P=0.17;I²=14%;TSA调整CI 0.61-1.09)。糖皮质激素组需要机械通气的风险较低(8项研究[1457例];RR 0.51;95%CI 0.33-0.77;P=0.001;I²=0%;TSA调整CI 0.20-0.85),但再入院率可能较高(5项研究[2853例];RR 1.20;95%CI 1.05-1.38;P=0.008;I²=0%;TSA调整CI 0.89-1.98)。ICU入住、治疗失败和不良事件发生率两组相似。
要点
- 住院CAP患者使用糖皮质激素与需要机械通气的风险降低相关:8项研究[1457例],RR 0.51(95%CI 0.33-0.77;P=0.001;I²=0%;TSA调整CI 0.20-0.85)。
- 全因死亡率无显著差异:16项研究[3842例],RR 0.85(95%CI 0.67-1.07;P=0.17;I²=14%;TSA调整CI 0.61-1.09)。
- 糖皮质激素使用可能与再入院率较高相关:5项研究[2853例],RR 1.20(95%CI 1.05-1.38;P=0.008;I²=0%;TSA调整CI 0.89-1.98)。
- 不良事件发生率两组相似:6项研究[2487例],RR 1.10(95%CI 0.97-1.25;P=0.14;I²=53%;TSA调整CI 0.82-2.41)。
- 治疗失败率两组相似:6项研究[2093例],RR 0.78(95%CI 0.37-1.67;P=0.52;I²=68%;TSA调整CI 0.02-25.5)。
适用人群与场景
- 需要住院的细菌性社区获得性肺炎(CAP)患者。
研究设计与关键结果
- 研究设计:系统评价、荟萃分析与试验序贯分析(TSA),纳入16项随机对照试验,比较全身性糖皮质激素与标准治疗在CAP管理中的效果。
- 主要终点全因死亡率:16项研究[3842例],RR 0.85(95%CI 0.67-1.07;P=0.17;I²=14%;TSA调整CI 0.61-1.09),糖皮质激素组与对照组相似。
- 需要机械通气:8项研究[1457例],RR 0.51(95%CI 0.33-0.77;P=0.001;I²=0%;TSA调整CI 0.20-0.85),糖皮质激素组低于标准治疗组。
- ICU入住:6项研究[2619例],RR 0.66(95%CI 0.45-0.97;P=0.04;I²=0%;TSA调整CI 0.37-1.12),糖皮质激素组与对照组相似。
- 治疗失败:6项研究[2093例],RR 0.78(95%CI 0.37-1.67;P=0.52;I²=68%;TSA调整CI 0.02-25.5),两组相似。
- 再入院:5项研究[2853例],RR 1.20(95%CI 1.05-1.38;P=0.008;I²=0%;TSA调整CI 0.89-1.98),糖皮质激素使用可能与再入院率较高相关。
- 不良事件发生率:6项研究[2487例],RR 1.10(95%CI 0.97-1.25;P=0.14;I²=53%;TSA调整CI 0.82-2.41),两组相似。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与荟萃分析。
对床旁实践的改变
- 住院CAP患者使用糖皮质激素与需要机械通气的风险降低相关(RR 0.51),但与死亡率、治疗失败或不良事件无显著关联,且可能与再入院率较高相关(RR 1.20)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. Corticosteroids may be a beneficial adjunct in the treatment of bacterial pneumonia.
RESEARCH QUESTION: Is there any benefit of corticosteroid therapy in the management of bacterial CAP among patients requiring hospitalization?
STUDY DESIGN AND METHODS: PubMed, Cochrane Library, and Embase were searched to identify randomized controlled trials assessing the use of systemic corticosteroids compared with standard care in the management of CAP. A systematic review, meta-analysis, and Trial Sequential Analysis (TSA) were performed. The primary outcome was all-cause mortality. Secondary outcomes included ICU admission, mechanical ventilation, treatment failure, readmission, and adverse events. Data are presented as risk ratio (RR) with 95% CI, P value, heterogeneity (I2), and TSA-adjusted CIs.
RESULTS: Sixteen trials met the eligibility criteria. All-cause mortality (16 studies [3,842 patients]; RR, 0.85 [95% CI, 0.67-1.07]; P = .17; I2 = 14%; TSA-adjusted CI, 0.61-1.09), ICU admission (six studies [2,619 patients]; RR, 0.66 [95% CI, 0.45-0.97]; P = .04; I2 = 0%; TSA-adjusted CI, 0.37-1.12), treatment failure (six studies [2,093 patients]; RR, 0.78 [95% CI, 0.37-1.67]; P = .52; I2 = 68%; TSA-adjusted CI, 0.02-25.5), and the incidence of adverse events (six studies [2,487 patients]; RR, 1.10 [95% CI, 0.97-1.25]; P = .14; I2 = 53%; TSA-adjusted CI, 0.82-2.41) were similar between patients receiving corticosteroids and patients assigned to the control group. The need for mechanical ventilation (eight studies [1,457 patients]; RR, 0.51 [95% CI, 0.33-0.77]; P = .001; I2 = 0%; TSA-adjusted CI, 0.20-0.85) was lower among patients receiving corticosteroids compared with those receiving standard care. However, corticosteroid use may be associated with higher rates of hospital readmission (five studies [2,853 patients]; RR, 1.20 [95% CI, 1.05-1.38]; P = .008; I2 = 0%; TSA-adjusted CI, 0.89-1.98).
INTERPRETATION: Corticosteroid therapy is associated with a lower incidence of progression to requiring mechanical ventilation among patients hospitalized with CAP. No association was found between corticosteroid therapy and mortality, treatment failure, or adverse events.
TRIAL REGISTRY: PROSPERO; No.: CRD42021279359; URL: https://www.crd.york.ac.uk/prospero/.
参考来源
- Saleem N, Kulkarni A, Snow TAC, et al. Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials. Chest. 2022. PMID: 36087797. doi:10.1016/j.chest.2022.08.2229
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。